COMMUNIQUÉS West-GlobeNewswire

OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
27/03/2024
Financial highlights €18.7 million available cash as of December 31 st , 2023, not including the upcoming $48 million payment as part of the recent collaboration and license partnership (February 2024) with AbbVie 1 , [...]
OSE Immunotherapeutics publie ses résultats financiers annuels 2023 et fait le point sur sa stratégie de développement
27/03/2024
OSE Immunotherapeutics publie ses résultats financiers annuels 2023 et fait le point sur sa stratégie de développement Principaux éléments financiers Position de trésorerie de 18,7 millions d’euros au 31 décembre 2023, [...]
Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy
27/03/2024
PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy [...]
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
27/03/2024
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical [...]
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
27/03/2024
Bexotegrast clinical poster selected for featured oral presentation at ATS 2024 Mini Symposium SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage [...]
Synaptive Medical Receives FDA 510(k) Clearance for Near-Infrared Fluorescence Visualization, Expanding Application of Existing Robotic Exoscope
27/03/2024
Near-Infrared fluorescence now available on Modus X robotic exoscope, complementing system’s existing advanced fluorescence capabilities New Infrared fluorescence enables the use of Modus X for visualization of vessels [...]
Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages
27/03/2024
IRVINE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets - NYMXF) is pleased to report that the Bahamas Supreme Court has issued a formal Order officially putting an end [...]
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
27/03/2024
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare [...]
Indkaldelse Til Ordinær Generalforsamling Den 18. April 2024 Kl. 15:00
27/03/2024
I henhold til vedtægternes pkt. 4.5 indkaldes hermed til ordinær generalforsamling i Orphazyme A/S til afholdelse den 18. april 2024 kl. 15:00 på selskabets adresse hos Visionhouse, Lyskær 8A, 2730 Herlev med følgende [...]
Tevogen Bio Announces Series A-1 Preferred Stock Investment
27/03/2024
WARREN, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell [...]
Metagenomi Reports Business Updates and Full Year 2023 Financial Results
27/03/2024
Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman primate durability data in 2H 2024 Proof of capability [...]
Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction
27/03/2024
PITTSBURGH, March 27, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the [...]
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
27/03/2024
Vancouver, Canada, March 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic- [...]
Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
27/03/2024
TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of [...]
Autonomix to Present at the MedInvest Biotech & Pharma Investor Conference
27/03/2024
Live webcast presentation on Thursday, April 4 th at 3:55 PM ET THE WOODLANDS, TX, March 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company [...]
NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry
27/03/2024
CARMEL, Ind., March 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
27/03/2024
Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM’s Diagnostic Research Programs in Dry Eye Disease and Parkinson’s SAN DIEGO, CA, March 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – AXIM Biotechnologies [...]
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend
27/03/2024
PALO ALTO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain [...]
NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday
27/03/2024
LANGHORNE, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content [...]

Pages